DiviDrip · EXEL

EXEL — Exelixis, Inc.

EXEL is Exelixis, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $65.50. Market cap: $16.18B. Capital Quality Rank: 100/100 — Market alpha.

Stock snapshot

Price$65.50
Market cap$16.18B
SectorHealthcare
ExchangeNMS
Pays dividendNo

Capital Quality & fundamentals

DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.

Capital Quality Rank (1-100)100 / 100 · Market alpha
ROIC (TTM)41.0%
Revenue CAGR (3y)12.9%
Shareholder buyback yield5.06%
Altman Z-score zoneSafe

Valuation, price chart & technicals

·Compounder — cheap for the growthPEGR40FCFALT+4

Valuation Multiples— the whole story at a glance

vs 1073 Healthcare peers (median)
18.80
vs Healthcare 23.74-21%
Stock trades 21% below sector median — 0.79× peer level.
14.27
vs Healthcare 16.75-15%
Stock trades 15% below sector median — 0.85× peer level.
6.64
vs Healthcare 3.38+96%
Stock trades at 1.96× sector median — 96% above peers.
0.47
vs Healthcare 1.44-68%
Stock trades 68% below sector median — 0.33× peer level.
15.58
vs Healthcare 11.64+34%
Stock trades at 1.34× sector median — 34% above peers.

PEG colour: ≤ 1.0 cheap · 1–2 fair · > 2 rich. Lower = the stock's price is rising slower than its growth.

Price Chart

+81.01%
Overlays
$36.08$43.39$50.70$58.00$65.31Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26Oct 26
RSI 14Overbought · Oversold
703050
Market Cap$16.18B
52 Week Range$65.50
$33.76$61.66
BetaLow Risk0.47
Day Range$65.50
$64.33$65.50
Volume1.71M vs Avg 2.36M

Technicals

SMA50$57.76
RSI1476.42Overbought

About EXEL

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Listed2000Employees1.1KHQAlameda, CASectorHealthcareWebsiteexelixis.com

Related non-dividend companies

Other non-dividend stocks investors research alongside EXEL. Peer set from Massive news + returns similarity, filtered to names we currently track.

Frequently asked

What is EXEL's current stock price?

EXEL (Exelixis, Inc.) is currently trading at $65.50.

Does EXEL pay a dividend?

EXEL (Exelixis, Inc.) does not currently pay a regular dividend.

What is EXEL's Capital Quality Rank?

EXEL has a Capital Quality Rank of 100/100 — Market alpha. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.

Track EXEL in DiviDrip

Add EXEL to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.

Data refreshed 2026-10-23. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.

Related guides

DiviDrip is a free dividend portfolio tracker built by dividend investors, for dividend investors. Try it free — no payment, no upsell, ever. Read the How-To to see how each tool fits together, or browse the Glossary for every term defined.

Disclaimer: The information provided on this website/service is for informational purposes only and does not constitute financial, investment, or legal advice. Investing in stocks involves high risk, including the loss of principal. We are not responsible for any financial losses or damages resulting from your reliance on this data. Always consult with a qualified financial professional before making investment decisions.

Trademark Notice: Twylight Crow's Dividend Tracker (formerly indexed as DiviDrip) is an independent portfolio utility. This tool is not affiliated with, authorized, endorsed by, or in any way officially connected to Dividrip.com or its international affiliates.

Dividend Reinvestment CalculatorContact: dividrip@twylightcrow.com© 2026 Twylight Crow